Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease

Current evidence suggests that gut dysbiosis drives obesity and non-alcoholic fatty liver disease (NAFLD) pathogenesis. Toll-like receptor 2 (TLR2) and TLR6 specifically recognize components of Gram-positive bacteria. Despite the potential implications of TLR2 in NAFLD pathogenesis, the role of TLR6 has not been addressed. Our aim is to study a potential role of TLR6 in obesity-related NAFLD. Forty morbidly obese patients undergoing bariatric surgery were prospectively studied. Cell surface expression of TLR2 and TLR6 was assessed on peripheral blood mononuclear cells (PBMCs) by flow cytometry. Freshly isolated monocytes were cultured with specific TLR2/TLR6 agonists and intracellular production of cytokines was determined by flow-cytometry. In liver biopsies, the expression of TLR2 and TLR6 was analyzed by immunohistochemistry and cytokine gene expression using RT-qPCR. TLR6 expression in PBMCs from non-alcoholic steatohepatitis (NASH) patients was significantly higher when compared to those from simple steatosis. The production of pro-inflammatory cytokines in response to TLR2/TLR6 stimulation was also significantly higher in patients with lobular inflammation. Hepatocyte expression of TLR6 but not that of TLR2 was increased in NAFLD patients compared to normal liver histology. Deregulated expression and activity of peripheral TLR6 in morbidly obese patients can mirror the liver inflammatory events that are well known drivers of obesity-related NASH pathogenesis. Moreover, TLR6 is also significantly overexpressed in the hepatocytes of NAFLD patients compared to their normal counterparts. Thus, deregulated TLR6 expression may potentiate TLR2-mediated liver inflammation in NAFLD pathogenesis, and also serve as a potential peripheral biomarker of obesity-related NASH.

[1]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[2]  D. Brenner,et al.  Interactions between the intestinal microbiome and liver diseases. , 2014, Gastroenterology.

[3]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[4]  N. Chalasani,et al.  Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease , 2012, Seminars in Liver Disease.

[5]  W. Jia,et al.  Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice , 2012, Gut.

[6]  D. Brenner,et al.  Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. , 2011, Alcoholism, clinical and experimental research.

[7]  M. López-Hoyos,et al.  Expression and function of toll-like receptors in peripheral blood mononuclear cells of patients with polymyalgia rheumatica and giant cell arteritis , 2011, Annals of the rheumatic diseases.

[8]  A. Dolganiuc,et al.  Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[9]  P. Adegboyega,et al.  Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis , 2010, BMC gastroenterology.

[10]  H. Ellingsgaard,et al.  Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet , 2010, Diabetologia.

[11]  R. Ley,et al.  Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5 , 2010, Science.

[12]  G. Tarantino,et al.  Could inflammatory markers help diagnose nonalcoholic steatohepatitis? , 2009, European journal of gastroenterology & hepatology.

[13]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[14]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[15]  H. Tilg,et al.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.

[16]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[17]  L. Romics,et al.  Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. , 2005, Alcoholism, clinical and experimental research.

[18]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[19]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[20]  N. Chalasani.  Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.

[21]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[22]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[24]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[25]  S. Akira,et al.  TLR6: A novel member of an expanding toll-like receptor family. , 1999, Gene.

[26]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[27]  J. Stockman,et al.  Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5 , 2012 .

[28]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.